# Bukwang Pharmaceutical Co > Bukwang Pharmaceutical Co is a VC fund backing Biotechnology and Health Care. See 3 investments, check sizes, portfolio and contact details. Updated Aug 2026. - Type: VC Fund - Location: Seoul, South Korea - Total investments: 3 - Last investment: Jan 2022 - Lead investor: 33% - Last updated: Aug 2026 - LinkedIn: https://www.linkedin.com/company/부광약품-주- - Website: http://www.bukwang.co.kr/ - Facebook: https://www.facebook.com/profile.php?id=268381373201053&paipv=0&eav=AfYH_8q37JpbZnDL5g1AHxKyYqf-lwseacFFqmuOMoQOlGTtRaMjMXRFVY71iTGVQ6o&_rdr Bukwang Pharmaceutical Co is a VC fund in Seoul focused on Biotechnology and Health Care. Bukwang Pharmaceutical Co., Ltd. was established on October 17th, 1960 and has since continued to produce excellent medications with the aim of improving global health for the last 55 years. Since Bukwang was listed in the Korea Stock Exchange in 1988, Bukwang is proud to have kept a healthy financial status and stable track record that earnedtrust from its employees and shareholders. Bukwang’s operating profit is at the top of the rank in the industry, nearing 20% as of financial year 2014.Bukwang’s armamentarium consists of more than 100 products in various therapeutic areas: liver disease treatments such as Levovir and Legalon, diabetic complication products such as Dexid and Thioctacid, CNS disorder drugs including Lonasen, Ixel and Orfil, and respiratory disease treatments such as Azeptin and Asima. Bukwang continues to grow its original drug business through consistent focus on new drug development. ## Contacts 5 contacts available for Bukwang Pharmaceutical Co. Shizune tracks 2 team members at Bukwang Pharmaceutical Co. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/bukwang-pharmaceutical-co?utm_source=investor_profile ## Investment focus ### Industry | Industry | Investments | Share | | --- | --- | --- | | Biotechnology | 2 | 67% | | Health Care | 1 | 33% | | Life Science | 1 | 33% | | Pharmaceutical | 1 | 33% | ### Stage | Stage | Investments | Share | | --- | --- | --- | | Series A | 1 | 33% | | Series B | 1 | 33% | | Funding Round | 1 | 33% | ### Country | Country | Investments | Share | | --- | --- | --- | | Israel | 1 | 33% | | United States | 1 | 33% | ## Team | Name | Title | Investments | Profile | | --- | --- | --- | --- | | Hee-Won Yoo | Co-President, Co-Chief Executive Officer & Director | 0 | — | | Sang-Hoon Kim | Co-President, Chief Strategy Officer & Director | 0 | — | ## Investments | Company | Description | Amount | Stage | Date | Website | | --- | --- | --- | --- | --- | --- | | ImmPACT Bio | ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues. | $139.9M | Series B | Jan 20, 2022 | | | ImmPACT Bio | ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues. | $18M | Series A | Aug 18, 2020 | | | Protekt Therapeutics | ProteKt Therapeutics is a drug development company aiming to develop potent and selective oral inhibitors of the kinase PKR for the treatment of neurodegenerative and neuroinflammatory diseases. The company has raised a $4M pre-A round and graduated from the FutuRx accelerator in 2019. | $4.1M | | Nov 12, 2019 | | 3 of 3 investments shown. ## Co-investors - [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 3 deals together - [Foresite Capital](https://shizune.co/investors/profile/foresite-capital) — VC Fund, 2 deals together - [Johnson & Johnson Innovation](https://shizune.co/investors/profile/johnson-johnson-innovation-jjdc) — VC Fund, 2 deals together - [Novartis Venture Fund](https://shizune.co/investors/profile/novartis-venture-fund) — VC Fund, 2 deals together - [RM Global Partners](https://shizune.co/investors/profile/rm-global-partners) — VC Fund, 2 deals together - [Takeda Ventures](https://shizune.co/investors/profile/takeda-ventures) — VC Fund, 2 deals together ## Similar investors ### Similar stage - [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund - [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund - [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund ## FAQ ### What does Bukwang Pharmaceutical Co invest in? Bukwang Pharmaceutical Co invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio. ### How do I contact Bukwang Pharmaceutical Co? Public channels for Bukwang Pharmaceutical Co include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox. ### Who are the partners at Bukwang Pharmaceutical Co? The team at Bukwang Pharmaceutical Co includes Hee-Won Yoo (Co-President, Co-Chief Executive Officer & Director) and Sang-Hoon Kim (Co-President, Chief Strategy Officer & Director). The Team section lists each member with their title, investment count and links. ### Is Shizune's investor data accurate? Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page. # About Shizune Shizune.co is an investor database. Core features: - 48,091 startup investors (angels, VCs, accelerators, and others) - Email, phone, LinkedIn (for intros), socials, and other contact data - Updated daily from public funding news - CSV and Excel export The User can access the full database FOR FREE after signing up: shizune.co